List of papers

1 Synthesis of 1,2-cis-substituted Glucosylglycerols, Zhurnal Obshchei Khimii, vol 49, 2148-50, 1979.

2 Selective benzylation of methyl 4,6-O- benzyliden --D-mannopyranoside, Rev.Cubana Farmacia, 1981, 15, 26-30

3 Synthesis of methyl 3-0-(  -D-mannopyranosyl)-  -D-glucopyranoside, Rev. Cubana Farmacia, 1981, 15, 164-8

4 Phase transfer benzylation of carbohydrates II. Synthesis of methyl 3-0-benzyl-4,6-0-benzyliden-  -D-galactopyranoside, Rev.Cubana Farmacia, 1981, 15, 169-73

5 Gas-chromatography analysis of the oligosaccharides present in Pisum sativum, Rev.Cubana Farmacia, 1981, 15, 222-6

6 Chromatography Determination of steroidal compound in solanum plants, Rev.Cubana Farmacia, 1981, 15, 247-251

7 Carbohydrates potentially antitumoral I. Alkyllthioglucosides, Rev.Cubana Farmacia, 1982, 16, 235-42

8 The synthesis of derivatives of 0--D-galactopyranosyl-(1-3)-0-(2-acetamido- 2-deoxy--D-galactopyranosyl)-L-serine and L-threonine , Carbohydr.Res.,1982, 110, C9-C11

9 Synthesis of glycopeptides having clusters of 0-glycosylic disaccharide chains [-D-Gal-(1-3)--D-GalNAc] located at vicinal amino acid residues of the peptide chain, Carbohydr.Res.,1983, 116, C9-C12.

10 Diosgenin, chlorogenin and Isochiapagenin from Solanum Bahamense L., Pharmazie 1982, 37, 225-226

11 Use of selenium in Carbohydrate Chemistry: Formation of vinyl-Glycosides, Synthesis, 1984,134-5

12 Synthesis of methyl 3-0-( 2-0- -D-mannopyranosyl  -D-mannopyranosyl)--D-glucopyranoside, Rev.Cubana Química, 1983, 17, 36-9

13 1,2-cis Glycosylation. Problems and solutions, Rev.Cubana Farmacia, 1983, 17, 40-54

14 1,2-cis Glycosylation. Synthesis of -mannosides, Rev.Cubana Farmacia, 1983, 17, 55-64.

15 Contribution of organic synthesis to the determination of human blood group MN specificity, Red Cell Membrane Glycoconjugates and related markers ed J.P.Cartron,P.Rouger,Ch.Salmon, Arnette, Paris 1983, 159-169

16 Synthesis of M and N active Glycopeptides. Part of the N-Terminal Region of Human Glycophorin A.,Glycoconjugate J.,1984,1,5-8

17 Interaction of synthetic Glycopeptides carrying clusters of 0-glycosidic disaccharide chains [b-D-Gal-(1-3)-a-D-GalNAc] with -D-Galactose-binding lectins,Glycoconjugate J.,1984,1,73-80

18 Steroidal glycosides from Solanum havanense Jacq, Rev.Cubana Quimica, 1986,2, II, 71-3

19 Synthesis of benzyl 3-0- benzyl -4,6-0-benzyliden- -D-galactopyranoside, Rev.Cubana Quimica, 1987,3,73-8.

20 Synthesis of disaccharides 2-acetamido-2-deoxi-3-0-- D-galactopyranosyl-D-galactose and D-glucose, Rev.Cubana Quimica, 1987,3,45-9.

21 An easy preparation of 2-deoxy-2-phtalimido--D-gluco- and -L-rhamno-pyranosides, J.Carbohydr.Chemistry, 1987, 6, 509-13.

22 Synthesis of allyl and benzyl 4-0-(3,6-di-0-methyl--D-glucopyranosyl) -2,3-di-0-methyl--L-rhamnopyranoside ,Carbohydr.Res.,1987, 165, 197-206.

23 Synthesis of disaccharide 2-acetamido-2-desoxi-- D-glucopyranosyl-(1-3)-D-galactose, the postulate receptor of pneumococci, Rev.Cubana Quimica, 1987,3,1-6.

24 Chemical synthesis of an artificial antigen containing the trisaccharide hapten of Mycobacterium leprae, Carbohydr.Res.,1988, 183, 175-82.

25 Inhibition studies of the specificity of the Vicia graminea lectin, Lectins; Biol.Biochem.,Clin Biochem., 1985, 4, 447-57

26 Serologic demonstration of the activity of a Mycobacterium leprae antigen obtained by chemical synthesis, Rev Cubana Med Trop. 1989, 41, 10-7

27 Glycosides of monoallyl diethylenglycol. A new type of spacer group for synthetic oligosaccharides. J.Carbohydrate Chemistry, 1989, 8, 531-7

28 Synthesis of the tetrasacaride Lacto-N-neotetraosa, Rev.Cubana Quimica, 1992,6,1-6.

29 An n.m.r. and conformational análisis of the terminal trisaccharide from the serologically active glycolipid of Mycobacterium leprae in different solvents. Carbohydr. Res., 1990, 200, 33-45

30 Glycosides of 8-hydroxi-3,6,-dioxaoctanal. A synthesis of a new spacer for synthetic oligosaccharides, Carbohydr.Res.,1991, 271, 263-7.

31 Ultramicroelisa para lepra con un antigeno sintetico. Revista do Instituto de Medicina Tropical de Sao Paulo, 1991, 33, 6, 491-5

32 Synthesis of the human blood group A trisaccharide with a dioxolane type spacer, Revista Cubana de Quimica, 1996, 8, 11-

33 Human Blood group B trisaccharide I. Synthesis , characterization and use for generation and selection of specific monoclonal antibodies, Biotecnologia aplicada, 1995, 12, 36-41

34 A new approach to the ribosyl-ribitol unit for the synthesis of Haemophilus influenzae type b oligosaccharides, J. Carbohydr.Chemistry , 1994, 13, 3, 465-74.

35 Synthesis of ribofuranosides by catalyst with Lewis acids. Glycosidation versus transacetylation, J. Carbohydrate Chem, 1995, 14, 551-561

36 Synthesis of the terminal disaccharides corresponding to Ogawa and Inaba antigenic determinant from Vibrio cholerae, Carbohydrate Letters, 1995,1, 173-178.

37 Synthesis of the trisaccharide -L-Rha-(1-2)--L-Rha-(1-2)--L-Rha with a dioxolane type spacer-arm, J. Carbohydr. Chem, 1996, 15, 137-146.

38 Synthesis of lex and ley oligosaccharides with azido-type spacer-arm. comparative use of 3- and 4-methoxybenzyl as a key temporal protective group, J. Carbohydr. Chem, 1998, 16, 7, 835-850.

39 Conjugate vaccines using synthetic carbohydrate antigens : a tool for anti-tumor therapeutics vaccines, Biotecnologia aplicada, 1997, 14, 56-7.

40 Synthesis of neoglycolipids containing man 3,6 branched oligosaccharides as a carbohydrate moeity, J. Carbohydr. Chem., 1998, 16, 7, 851-868.

41 Synthesis of the Vibrio cholerae O1 Ogawa and Inaba terminal disaccharides with a dioxolane-type spacer and their coupling to proteins, J. Carbohydrate Chem, 1998, 17 (9) 1307-1320.

42 Synthesis of terminal disaccharides corresponding to Ogawa and Inaba antigenic determinant from Vibrio cholerae O1, Carbohydrate Res. 1998, 306, 165-17

43 Synthesis of inmunogens containing lewisa and lewisb haptens by the use of glycosides of 5-azido-3-oxapentanol, Glycoconj J., 1998, 15, 549-553.

44 Synthesis and SOD-Like Activity of Monosaccharide Derived Thiosemicarbazones Journal of Carbohydrate Chemistry, 1998,17, 293 – 303

45 Galactosylation with -Galactosidase from Bovine Testes Employing Modified Acceptor Substrates, Bioorganic and Medicinal Chemistry, 1997, 5, 1285-1291

46 Effect of shape, size, and valency of multivalent mannosides on their binding properties to phytohemagglutinins, Glycoconjugate Journal, 1998, 15, 251-263.

47 Synthesis of new neoglycolipid (AgH-1) and its effect upon the properties of dipalmitoylphosphatidylcholine:cholesterol liposomes, Archiv. Biochem. Biophys., 1998, 350, 137-47.

48 Aggregation induced by concanavalin A of lipid vesicles containing neoglycolipids, Colloids and surfaces B: Biointerfaces 26(3):281-289

49 Synthesis and NMR analysis of 13C-labeled oligosaccharides corresponding to the major glycolipid from Mycobacterium leprae, Carbohydr. Res., 1998, 306, 493-503

50 Synthesis of dimeric Lewis X antigenic determinant with azido-type spacer arm by a sequence of regioselective glycosylation steps, Tetrahedron Letters, 1998, 9143-9146.

51 Synthesis of the amino spacered sialyl--(26)-lactosamine trisaccharide, Carbohydr. Res., 1999, 317, 29-38.

52 Solution conformation and dynamics of the trisaccharide fragments of the O-antigen of Vibrio cholerae O1, serotypes Inaba and Ogawa, Carbohydrate Research 1999, 321:1-2:88 – 95.

53 Synthesis of A Type 2 Tetrasaccharide with amino type spacer arm by Regio-Stereo Selective Glycosylation Strategy, Carbohydrate Letters, 1999, 3, 369-374.

54 Phase and surface properties of lipid bilayers containing neoglycolipids. Arch Biochem Biophys. 1999, 363(1):81-90.

55 Preparación de un inmunoadsorbente del grupo sanguíneo humano A para su uso en la purificación de hemoderivados, Acta Farm. Bonaerense 1999, 18 (3) 207-15.

56 Monosialyllactose neoglycoconjugates are not able to provide an immunological response against n-acetyl GM3 ganglioside in mice and chickens, Biotecnolog. Applic.2004, 21, 5-12.

57 Synthesis of Neoglycolipid Analogues of the Oligosaccharide Portion of Ganglioside GM3, J. Carbohydr. Chem., 2003, 22, 395-406

58 A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus Influenzae Type b, Science, 2004, 305, 522-24.

59 Immunogenicity and antigenicity of a synthetic Haemophilus influenzae type b oligosaccharide-protein conjugates, Infection and Immunity, 2004, 72, 7115-7123.

60 Método alternativo para la síntesis de una de las materias primas de la vacuna contra el Haemophilus influenzae tipo b, Revista Cubana de Química, 2005, 18, , 261

61 Phase I Evaluation of a conjugate vaccine containing fully synthetic Haemophilus influenzae type b oligosaccharides in Healthy Adults, Clinical Vaccine Immunology, 2006, 13, 1052-1056.

62 Polysaccharide-based vaccine, in Glycosciences, 2007, Ch75, pp 2699-2723

63 Development of Haemophilus influenzae type b conjugate vaccine with a synthetic capsular polysaccharide antigen. ACS Symposium series 2008, 989, 71-84

64 Glycoconjugate vaccines against Haemophilus influenzae type b. Methods in Enzymology, 2006, 415, 10, 153-163.

65 Enzyme-linked immunosorbent assay for quantitative determination of capsular polysaccharide in culture supernatants of Streptococcus pneumoniae, Biotechnology Applied Biochem, 2006, 44, 101-108.

66 T-cell immunity and carbohydrates, ACS Symposium series 2008, 989, 1-20

67 High performance reverse phase chromatography with fluorescence detection assay for characterization and quantification of pneumococcal polysaccharides, Vaccine, 2006, 24, Suppl 2, S2:70-1

68 CARACTERIZACIÓN DE LOS INTERMEDIARIOS SINTÉTICOS DE N-GLICOLIL GM3 POR RMN1H. Revista Cubana de Química, vol. XXI, núm. 1, 2009, pp. 20-24

69 Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy, Expert Opinion on Biological Therapy, 2010, Vol. 10, 153-162.

70 Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an α-1,6-glucan chain, Vaccine, 2012, 30, 7332-41.

71 Quantitative proton magnetic resonance determination of N,N-dimethylformamide in one intermediate of the Quimi-Hib vaccine. Magn. Reson. Chem.. 2012, 50(8):525-8

2013

72 Relevance of O-acetyl and phosphoglycerol groups for the antigenicity of Streptococcus pneumoniae serotype 18C capsular polysaccharide, Vaccine 30 (2012) 7090– 7096

73 A New and Efficient Approach to Prepare N‑Acetyl GM3 Ganglioside via Trisaccharide [1→4] Lactone, Org. Process Res. Dev. 2013, 17, 53−60

74 Quantitative Proton Nuclear Magnetic Resonance evaluation and total assignment of the capsular polysaccharide Neisseria meningitidis serogroup X, J Pharmaceutical and Biomedical Analysis 70 (2012) 295– 300

75 Resonancia magnética nuclear: nuevas aplicaciones en la cuantificación y la evaluación de intermediarios de vacunas basadas en polisacáridos, VacciMonitor 2013;22(1):35-42

76 Caracterización de conjugados inmunogénicos de polisacárido capsular Streptococcus pneumoniae serotipo 14, VacciMonitor 2013;22(1):15-21

77 Procedure for the conjugation of the Streptococcus pneumoniae serotype 6B capsular polysaccharide to the tetanus toxoid. Biotecnología Aplicada 2013;30:208-215

78 Characterization of the Streptococcus pneumoniae serotype 18C capsular polysaccharide by the combination of Chromatographical methods and 1H RMN, Revista CENIC Ciencias Químicas, 2013, 44, 57-67.

2014

79 Antibacterial and antifungal conjugate vaccine base on synthetic oligosaccharides, SPR Carbohydrate Chemistry Volume 40, 2014, pages 564-595.

80 Chapter 4.4. Vaccines against bacterial pathogens in Carbohydrates Chemistry: State-of-the-art and challenges for drug development, F. Nicotra and L. Cipolla Eds, Imperial College Press, 2014, chapter 12, 301-319

81 Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children. A randomized phase I clinical trial, Vaccine, 2014, 32 5266–5270

2015

82 From capsular polysaccharide to a conjugate vaccine containing Haemophilus influenzae type b synthetic oligosaccharide in ¨Carbohydrates in Drug Discovery and Design” 2015, chapter 12, 285-307

83 Safety and Immunogenicity of Cuban Antipneumococcal Conjugate Vaccine PCV7-TT in Healthy Adults, MEDICC Review, 2015, Vol 17, 32-37

2017

84 Prevalence of Pneumococcal Nasopharyngeal Carriage Among Children 2–18 Months of Age, Pediatr Infect Dis J 2017;36:e22–e28

85 La nueva vacuna cubana antineumocócica, de las evidencias científicas disponibles, a la estrategia de evaluación clínica y de impacto, Rev Cubana Pediatr. 2017;89(sup)

86 Activación del polisacárido capsular de Streptococcus pneumoniae serotipo 23F para la obtención de vacunas conjugadas, VacciMonitor 2017, 26, 8-16

87 Influence of the Co-Administration of Heptavalent Conjugate Vaccine PCV7-TT on the Immunological Response Elicited by VA-MENGOC-BC® and Heberpenta®-L in Rabbits, Immunological Investigations, 2017, 1532-4311

88 Self-assembled particulate PsaA as vaccine against Streptococcus pneumoniae infection, heliyon, 2017.e00291

89 NMR line-fitting quantification of polysaccharide N-acylurea-based modification in glycoconjugates of Salmonella Typhi Vi polysaccharide, Magn Reson Chem. 2017 Jan 14. doi: 10.1002

90 From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy, International Journal of Infectious Diseases, 2017, 60, 98-102

2018

91 Multicomponent Polysaccharide-Protein Bioconjugation in the Development of Antibacterial Glycoconjugate Vaccine Candidates, Chemical Science, 2018, 9, 2581

92 Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection, Scientific Reports, 2018, 8, 1888

93 Evaluation Strategy to Support the Introduction the New Cuban Conjugated Pneumococcal Vaccine in the National Health System, J Vaccines Vaccin, 2018, 9:1

94 Design and biological assembly of polyester beads displaying pneumococcal antigens as a particulate vaccine, ACS Biomaterials Science & Engineering, 2018, 49, 3413-3424

95 Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I, Vaccine, 36, 2018, 4944

96 Effectiveness of a Serogroup B and C Meningococcal Vaccine developed in Cuba, MEDICC Review, 2018, 20, 22-29

2019

97 Colonización nasofaríngea por Streptococus pneumoniae en niños prescolares cubanos: encuestas transversales antes-después de la vacunación antineumocócica, Vacunas, 2019, 2 0(1) 3–11

98 Synthetic zwitterionic Sp1 oligosaccharides adopt a helical structure crucial for antibody interaction, ACS Cent. Sci. 2019, 5, 8, 1407-1416

2020

99 Vaccination Achievements of Cuba Versus the United States Exposed by the 2019 Measles Epidemic, American Journal of Public Health, 2020, Vol 110, 469

100 SARS-CoV-2 Carbohydrate-Mediated Interactions at the Host-Pathogen Interface, https://doi.org/10.1101/2020.05.13.092478

101 Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates, Bioconjugate Chem. 2020, 31, 9, 2231–2240 https://doi.org/10.1021/acs.bioconjchem.0c00423

2021

102 Las vacunas Soberana como continuidad de la obra del Dr. Carlos J. Finlay. Reflexión en homenaje a su nacimiento y al Día de la Medicina Panamericana, Anales de la ACC, 2021, 11,

103 Molecular aspects concerning the use of SARS-CoV-2 Receptor Binding Domain as the target for preventive vaccines, ACS Cent. Sci. 2021, 7, 757-767. https://doi.org/10.1021/acscentsci.1c00216

104 SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity, ACS Chem. Biol. 2021, 16, 7, 1223–1233, https://doi.org/10.1101/2021.02.08.430146

105 A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial, LANAM, 2021, 4, 100079 https://doi.org/10.1016/j.lana.2021.100079

106 Glycan array evaluation of synthetic epitopes between the capsular polysaccharides from Streptococcus pneumoniae 19F and 19A. ACS Chemical Biology, 2021, 16, 1671-79 https://doi=10.1021/acschembio.1c00347&ref=pdf

107 In-solution buffer-free digestion for the analysis of SARS-CoV-2 RBD protein allows a full sequence coverage and PTM characterization in a single ESI-MS spectrum. Analytical and Bioanalytical Chemistry. 2021, 413(30): 7559-7585.

2022

108 A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity, Vaccine 2022 Mar 18; 40(13): 2068–2075

109 A COVID-19 vaccine candidate composed of SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles. RSC Chem. Biol., 2022, 2022, 3, 242-249 DOI: 10.1039/D1CB00200G

110 Safety and Immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA02 in homologous or heterologous scheme. Pooled analysis of Phase I/IIa clinical trials. Vaccine, 2022, 40, 4220-4230

111 Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses combination, MedRxiv preprint doi: https://doi.org/10.1101/2021.10.31.21265703. LANAM, accepted

112 Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial. Med (Cell), https://doi.org/10.1016/j.medj.2022.08.001

113 Efficacy and Safety of a protein-based SARS-CoV-2 vaccine (SOBERANA 02 and SOBERANA Plus): a double-blind, randomized, placebo-controlled, phase 3 trial in Iran, Lancet accepted

114 Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: novel preclinical mix and match rAd5 S, rAd5 RBD-N and Soberana dimeric-RBD protein, Vaccine 2022, 40, 2856-2868

115 Repeat-Dose and Local Tolerance Toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats, Toxicology, 2022, 471, 153161. doi: 10.1016/j.tox.2022.153161.

116 An open-label phase IIa and double-blind, randomised, placebo-controlled phase IIb clinical trial of FINLAY-FR-1A vaccine confirmed its safety and immunogenicity in COVID-19 convalescents, Lancet Respiratory Medicine, 2022, 10(8):785-795.

117 Safety, immunogenicity and predictive efficacy of SOBERANA 02 as two doses scheme or heterologous three doses with SOBERANA Plus in children 3-18 years old: open label Phase I/II clinical trial, International Journal of Infectious Diseases, accepted

118 Quantitative NMR for the structural analysis of novel bivalent glycoconjugates as vaccine candidates, J Pharmaceutical and Biomedical Analysis, Volume 2022, 214, 114721 https://doi.org/10.1016/j.jpba.2022.114721

119 Estandarización de un procedimiento espectrofotométrico para la cuantificación de polisacárido capsular de Neisseria meningitidis serogrupo X, VacciMonitor 2022;31(2):83-89

120 PastoCovac Plus® Vaccine as a Protein Subunit Booster Significantly Raised Specific SARS-CoV-2 Antibodies in BBV152 Vaccinated Iranian Health Care Workers, Clinical Microbiology and Infection, Submitted